MNG957
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.264
- MYOGENESIS+0.258
- KRAS_SIGNALING_DN+0.183
- UV_RESPONSE_DN+0.168
- ESTROGEN_RESPONSE_EARLY+0.139
- APICAL_SURFACE+0.106
- BILE_ACID_METABOLISM+0.104
- PEROXISOME+0.087
- SPERMATOGENESIS+0.063
- APICAL_JUNCTION+0.043
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.532
- TNFA_SIGNALING_VIA_NFKB-0.464
- ALLOGRAFT_REJECTION-0.393
- IL6_JAK_STAT3_SIGNALING-0.390
- ANGIOGENESIS-0.383
- G2M_CHECKPOINT-0.376
- NOTCH_SIGNALING-0.373
- E2F_TARGETS-0.348
- MYC_TARGETS_V1-0.345
- INFLAMMATORY_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1358501 | GTEX | — | 0.896 |
| 2 | MNG491 | — | — | 0.875 |
| 3 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.873 |
| 4 | SRR1339740 | GTEX | — | 0.870 |
| 5 | SRR821581 | GTEX | — | 0.869 |
| 6 | BS_063ERW0R | pilocytic astrocytoma | — | 0.864 |
| 7 | BS_0Y66ZBWE | low-grade glioma | — | 0.861 |
| 8 | BS_0T17SY47 | low-grade glioma | — | 0.859 |
| 9 | MNG540 | — | — | 0.858 |
| 10 | SRR1404640 | GTEX | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.264 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.258 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.183 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.168 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.139 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.106 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.104 | Inavolisib | — uncovered |
| PEROXISOME | 0.087 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.063 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.043 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.043 | Remibrutinib | — uncovered |